Pharmacogenetic testing for warfarin dosing still awaits validation.


The recently published MM-WES study (Medco-Mayo Warfarin Effectiveness Study) (1) addresses an urgent need for evidence in the area of pharmacogenomics, in this case the potential impact on clinical outcomes of pharmacogenetic testing for guiding warfarin dosing. However, serious design flaws preclude drawing reliable conclusions from this study. Modest… (More)
DOI: 10.1016/j.jacc.2010.07.057


  • Presentations referencing similar topics